A New PrEP Pill: Brazil’s Large-Scale Test of a Long-Acting HIV Shield
A major implementation study investigating lenacapavir for HIV pre-exposure prophylaxis (PrEP) has launched in Brazil. The ImPrEP LEN Brasil study, which began in January 2026, is enrolling young adults across seven cities to assess the real-world effectiveness of this long-acting injectable agent. Lenacapavir is a novel capsid inhibitor with a unique mechanism and a twice-yearly dosing schedule, representing a significant shift from daily oral PrEP regimens. This large-scale study aims to determine if its extended protection can overcome adherence challenges and reduce HIV incidence in a key demographic.
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
